ABSTRACT Objectives
With 1% prevalence worldwide, rheumatoid arthritis (RA) is a common form of arthritis that, although the onset of RA is more frequent later in life, can affect people at any age. Without adequate treatment, this severe chronic infl ammatory joint disease inevitably causes loss of articular function and mobility. Even though effective therapeutics are now available against the progression of the disease, additional therapeutic options are still needed when current therapies fail or cause severe adverse effects. This is where the so-called adipocytokines may come into play.
The major source of adipocytokines is adipose tissue. It has now become evident that adipose tissue is not merely an immunologically inactive EXTENDED REPORT Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis? Klaus W Frommer, 1 Andreas Schäffl er, 2 Christa Büchler, 2 Jürgen Steinmeyer, 3 Markus Rickert, 4 Stefan Rehart, 5 Fabia Brentano, 6 Steffen Gay, 6 Ulf Müller-Ladner, 1 Elena Neumann 1 type of connective tissue but also an important immunoendocrine organ producing hormones and cytokines. [1] [2] [3] These factors have been collectively termed adipocytokines or, in short, adipokines. Adiponectin, leptin, resistin and visfatin are just a few examples of this growing number of highly bioactive substances with metabolic and immunological functions. 4 5 Pathologically, adipokines appear to be involved in numerous chronic infl ammatory diseases. This not only includes RA but also systemic lupus erythematosus, ankylosing spondylitis and systemic sclerosis. 6 Synovial hyperplasia accompanied by substantial infl ammation and degradation of joints 7 is a key feature of RA, and rheumatoid arthritis synovial fi broblasts (RASF) are a major player in these destructive processes. [8] [9] [10] This RA-specifi c cell type therefore presents a promising target for therapeutic intervention. For that reason, we investigated the effects of the adipocytokine adiponectin on RASF in order to fi nd out how this may affect the pathogenesis of RA.
Adiponectin, a C1q/tumour necrosis factor (TNF) homologue, 11 lent itself to this question as its synovial fl uid levels are signifi cantly increased in RA patients compared with osteoarthritis patients as well as healthy controls, 12 13 and hyperadiponectinemia is associated with an increased incidence of joint destruction 14 or radiographic progression 15 16 in RA patients. Of note, adiponectin is not only produced by adipose tissue but also by synovial fi broblasts, endothelial cells, osteoblasts and cardiac myocytes. [17] [18] [19] In a previous study, 20 we were able to show that native adiponectin affects several RA effector cells.
Interestingly, adiponectin is not a homogenous entity but consists of several isoforms corresponding to different oligomers with a 'bouquet of fl ower' structure. Trimeric adiponectin, also called low molecular weight adiponectin, is composed of three full-length adiponectin monomers forming a collagen triple helix with a C-terminal globular gC1q domain (head domain). 21 Globular adiponectin consists of the head domain of trimeric adiponectin as a result of proteolytic cleavage. [22] [23] [24] The adiponectin hexamer, the so-called middle molecular weight (MMW) adiponectin, is a combination of two trimeric adiponectin molecules, while an assembly of 12-18 monomers is collectively termed high molecular weight (HMW) adiponectin. 21 Even though some studies have investigated selected adiponectin isoforms, 21 25-28 no studies have yet analysed the potentially differential effects of adiponectin isoforms on effector cells involved in the pathophysiology of RA.
With adiponectin's important functions in energy metabolism and benefi cial effects on the cardiovascular system, 29 30 it might be unadvisable to modulate adiponectin levels systemically in order to prevent its disease-promoting effects in RA. Instead, inhibiting adiponectin locally at sites of joint destruction or targeting specifi c isoforms could be viable options. Therefore, in this study we investigated whether adiponectin isoforms differentially affect gene expression and protein secretion of RASF, and could thus provide targets for specifically inhibiting the detrimental effects of adiponectin while preserving its benefi cial effects. As rheumatoid synovium is strongly infi ltrated by lymphocytes and migrating RASF, which can additionally invade the synovium and cartilage, 8 we also analysed whether the factors induced by the different adiponectin isoforms in RASF have chemoattractive properties on RASF and lymphocytes.
MATERIALS AND METHODS

Cell culture
Human primary synovial fi broblasts and primary lymphocytes were cultured as described in the supplementary material (available online only).
Isolation of synovial fi broblasts
Synovial tissue samples were obtained from synovial biopsy specimens from RA and osteoarthritis patients who were undergoing joint surgery. All specimens were obtained with the approval of the Ethics Committee of the Justus-LiebigUniversity of Giessen. All patients gave informed consent and fulfi lled the criteria of the American College of Rheumatology. 31 32 Following enzymatic digestion, 33 34 primary synovial fi broblasts were isolated and cultured in supplemented Dulbecco's modifi ed Eagle's medium as described previously. 20 
Isolation of lymphocytes from human whole blood
Lymphocytes were isolated by Ficoll-based density gradient centrifugation as described in more detail in the supplementary material (available online only). RASF (n=1) were treated with adiponectin isoforms or left untreated (control). Affymetrix microarray analysis (GeneChip HG U133A) was performed as described.
The results indicate that genes from several functional groups are differentially regulated in RASF by adiponectin isoforms. The cut-off value for fold changes was ≤2 (repression) or ≥2 (induction), respectively. Strongly repressed genes were low in number and of no known or well-defi ned function. Ad, adiponectin; gAd, globular adiponectin; HMW, high molecular weight; MMW, middle molecular weight; RASF, rheumatoid arthritis synovial fi broblasts.
Stimulation of RASF and OASF
RASF and osteoarthritis synovial fi broblasts (OASF) from passages 3-8 were grown to 70-80% confl uency and stimulated with 25 μg/ml of different human adiponectin forms (BioVendor, Heidelberg, Germany) for 15 h: native adiponectin (a mixture of different adiponectin isoforms; recombinantly produced in HEK 293 cells); HMW/MMW-enriched adiponectin (recombinantly produced in HEK 293 cells); trimeric adiponectin (recombinantly produced in HEK 293 cells; prevented from further oligomerisation by a single amino acid mutation) and globular adiponectin (recombinantly produced in Eschericia coli). Sodium dodecylsulphate polyacrylamide gel electrophoresis analysis images of the commercially available adiponectin preparations, which were used, are shown in supplementary fi gure S1 (available online only). The stimulation time was chosen based on preliminary experiments that demonstrated optimal response after 15 h. 18 Unstimulated RASF and OASF were used as negative controls. Dose-response analyses were performed previously 18 and showed that the induction of interleukin (IL)-6 and pro-matrix metalloproteinase (MMP) 1 by adiponectin does not reach a plateau until a concentration of approximately 100 μg/ml. We additionally showed that potential lipopolysaccharide contaminations of recombinant adiponectin were not responsible for the effects observed after stimulation. 20 Affymetrix gene chips RASF (passage 5; n=1) were stimulated for 15 h with 25 μg/ml of the different adiponectin isoforms as described above. Affymetrix (Santa Clara, CA, USA) microarray analysis was performed as described in the supplementary material (available online only).
Real-time PCR
Reverse transcription of RNA and real-time PCR were performed as described in the supplementary material (available online only).
Immunoassays
The cytokine, chemokine, MMP and adiponectin levels in cell culture supernatants were measured using commercially available ELISA (R&D Systems, Wiesbaden, Germany).
Two-chamber migration assay
Media from adiponectin-stimulated RASF were analysed for their chemoattractive potential on RASF and lymphocytes using a two-chamber migration system. The procedure is described in detail in the supplementary material (available online only).
Statistical analysis
Biological or experimental replicates were used to calculate arithmetic means and standard errors of the mean (SEM). Data are presented as the mean±SEM. In order to assess the signifi cance of differences, a Student's two-tailed t test was performed for pairwise comparisons. For multiple comparisons, analysis of variance including Tukey's post-hoc test was performed. p Values less than 0.05 were considered signifi cant. Statistical calculations were performed using Microsoft Excel and GraphPad Prism.
RESULTS
Differential induction of chemokines in RASF by adiponectin isoforms
RASF are an RA-specifi c cell type capable of driving infl ammation and joint destruction, 9 of invading into cartilage, 35 and of migrating from joint to joint. 8 Inhibiting their destructive activity is a desirable goal in RA therapy. Factors that promote or inhibit this activity are thus of substantial interest as potential therapeutic targets. We therefore analysed the effects of the different adiponectin isoforms on RASF gene expression, focusing on fi nding out whether there are differences in the effects of the adiponectin isoforms and to what degree each isoform might be involved in RA pathogenesis. First, Affymetrix microarray analysis (GeneChip HG U133A) was performed in order to compare the gene expression of RASF stimulated with the different adiponectin isoforms or RASF left unstimulated. As large amounts of messenger RNA are required for Affymetrix microarrays and patient material was limited, one RASF population (n=1) was analysed exemplarily in this experiment to screen for changes in gene expression. The variability of different RASF populations was later accounted for by verifying selected results with higher n numbers. Chemokines were the largest group of dysregulated genes and were differentially induced by the adiponectin isoforms (table 1). Verifi cation of selected chemokines (GRO-α/-β/-γ, ENA-78, GCP-2, MCP-1, MCP-3) by real-time PCR confi rmed the differential induction of mRNA expression in multiple RASF populations (table 2 and fi gure 1A). Using immunoassays, we confi rmed that chemokine secretion (GRO-α, ENA-78, GCP-2, IL-8, MCP-1, RANTES) was also differentially regulated by the individual adiponectin isoforms (table 3 and fi gure 1B). I-TAC (CXCL11) and MIP-3α (CCL20) protein, however, could not be detected in either cell culture supernatants or cell lysates (data not shown). In particular, within the real-time PCR and immunoassay results, we could identify a distinct pattern regarding the effect of the different adiponectin isoforms on RASF; overall, HMW/MMW-enriched and globular adiponectin were the most potent isoforms, while the adiponectin trimer was the least effective. Native adiponectin, which has not been enriched for any isoform, mostly held a middle ground but was rather variable in its potency depending on the regulated gene or protein. These observations are illustrated in fi gure 1.
Differential induction of cytokines, MMP and other RA-related genes in RASF by adiponectin isoforms
Not only chemokines, but also pro-infl ammatory cytokines, MMP and infl ammation-related enzymes play a major role in RA pathogenesis. Their regulation is therefore crucial.
Our results showed that cytokines, MMP and other RA-related molecules were also regulated to very different extents depending on the particular adiponectin isoform (tables 1 and 3, fi gure 1B). For example, secretion of the pro-infl ammatory cytokine IL-6 was most strongly induced by HMW/MMW-enriched adiponectin, while the weakest response was seen with trimeric adiponectin. Similar differential inductions by the individual adiponectin isoforms could be observed for the infl ammation-related enzyme cyclooxygenase 2 (COX2) as well as the MMP 1, 3, 10 and 12.
Biological variability of RASF cell populations in response to adiponectin stimulation
Different RASF cell populations, ie, synovial fi broblasts obtained from different RA patients, showed highly variable responses to stimulation with adiponectin. Adiponectin upregulated gene expression or protein secretion in all cell populations that were analysed but to very different extents, which is illustrated in fi gure 2A.
Response of OASF to adiponectin stimulation in comparison with RASF
Synovial fi broblasts from RA patients and osteoarthritis patients responded similarly to stimulation with adiponectin isoforms, but OASF generally showed a weaker mean response than RASF, demonstrating the special phenotype of RASF (fi gure 2B). However, due to the high biological variability of the cell populations, statistical signifi cance for the differences between RASF and OASF responses could not be reached in most cases. Although the differences in the response towards the different adiponectin isoforms were not as prominent as for RASF, differences could also be detected for OASF.
Chemoattractive effect of adiponectin-induced factors on RASF and lymphocytes
As outlined above, adiponectin isoforms induced numerous chemokines. We therefore investigated to what extent this leads to a functional chemoattractive effect on RASF and lymphocytes, two key cell types in RA. A two-chamber migration assay was performed with RASF and primary human lymphocytes. Conditioned media from RASF cultures incubated with the different adiponectin isoforms were used as potential chemoattractants against medium from unstimulated RASF incubated in parallel. RASF were allowed to migrate for 15 h, lymphocytes for 4 h. Cells that actively passed the membrane of the two-chamber migration system were counted. The gradientfree baseline was set to 100%. Here, we observed an increased migration for RASF and lymphocytes towards conditioned medium from adiponectinstimulated RASF, indicating that the adiponectin-induced factors have a signifi cant chemoattractive effect on RASF (n=3) . Medium from RASF stimulated with different adiponectin isoforms was used in a two-chamber migration assay as a chemoattractant for RASF (n=3). The baseline (without chemotactic gradient) was set to 100%. Migration of RASF is expressed relative to the baseline. Using serum-free medium as a chemorepellent decreased RASF migration to 38%, while using 10% fetal calf serum medium as a positive control increased RASF migration by 278% (data not shown). (B) Chemoattractive effect of adiponectin-induced factors on lymphocytes. Medium from RASF stimulated with different adiponectin isoforms was used in a two-chamber migration assay as a chemoattractant for lymphocyte (n=3) and analysed as described above. Using serum-free medium as a chemorepellent decreased lymphocyte migration to 35%, while using RANTES (10 ng/ml) plus SDF (Stromal CellDerived Factor) (100 ng/ml) as a positive control increased lymphocyte migration by 345% (data not shown). Data are shown as the mean±SEM. *p<0.05; **p<0.01; ***p<0.001. HMW, high molecular weight; MMW, middle molecular weight.
(fi gure 3A) and lymphocytes (n=3) (fi gure 3B). Additional controls with adiponectin (25 μg/ml) added just before the start of the migration assay showed that adiponectin itself does not have any chemoattractive properties on the cell types analysed (data not shown).
In summary, factors induced by adiponectin isoforms had a differential effect on RASF and lymphocyte migration, thus refl ecting the individual effects of the respective adiponectin isoforms on protein secretion by RASF.
DISCUSSION
The primary objective of this study was to investigate if the different isoforms of the adipokine adiponectin have differential effects on RASF, a key cell type in RA pathogenesis. Previous data 14-16 20 have suggested that adiponectin may be rather detrimental in RA and involved in disease progression. However, as available data have indicated that adiponectin is benefi cial for metabolic and cardiovascular health, 29 30 systemic elimination in order to avoid the harmful effects in RA might not be a favourable option. Based on initial data, 27 28 researchers concluded that mainly HMW adiponectin is responsible for the vascularprotective effects of adiponectin. On the other hand, available data have suggested that adiponectin promotes RA progression [14] [15] [16] and does this most likely by inducing the secretion of pro-infl ammatory molecules (eg, IL-6, COX-2), chemokines (eg, IL-8, MCP-1) and matrix-degrading enzymes (eg, MMP3). 20 Adiponectin is thus able to mount and sustain a pro-infl ammatory response in various pathophysiologically relevant cell types in RA and osteoarthritis, including chondrocytes 20 36 37 and RASF, 20 both of which share the common characteristics of mesenchymal-derived cells.
These results led to the hypothesis that inhibition of specifi c adiponectin isoforms might help circumvent the problem of reducing the harmful effects of adiponectin in RA while maintaining its benefi cial effects. However, our results showed that even though the individual adiponectin isoforms have different potencies to modulate gene expression of RASF they do not have opposing effects or no effect at all in the setting of RA pathophysiology. Nonetheless, our results suggest that certain isoforms of adiponectin are more detrimental in RA than others. Therefore, when considering adiponectin as a progression or activity marker for RA, it may be best to look at the most potent isoforms.
With regard to functional aspects of adiponectin isoforms, we were able to show that adiponectin-induced factors promote the migration of RASF and lymphocytes in vitro, which in vivo may lead to increased synovial lymphocyte infi ltration and additional infl ux of RASF to sites of infl ammation and cartilage degradation. Inhibition of these processes by blocking the local effects of specifi c adiponectin isoforms within the joints could therefore lead to reduced disease progression and activity.
Another interesting observation was the high variability of RASF in response to adiponectin isoform stimulation, which may be attributed to different genetic profi les 38 39 as well as epigenetic variations between RASF populations. 40 This is also in line with clinical fi ndings showing that there are considerable differences in how RA patients respond to the different available medications. RASF possess a special phenotype refl ected not only in their ability to migrate and invade into cartilage, 8 but also in their ability to respond to external stimuli such as adiponectin, which was illustrated here by the weaker response of OASF to adiponectin compared with RASF.
When considering strategies for modulating the effects of adiponectin, there are other conceivable options besides modulating adiponectin itself: targeting adiponectin receptors [41] [42] [43] or co-receptors, [44] [45] [46] [47] and inhibiting the oligomerisation of adiponectin isoforms by small molecule inhibitors that prevent the assembly into higher molecular weight isoforms.
With respect to animal models, the viability of adiponectin knock-out mice indicates that, at least in mice, adiponectin is not vital, but results regarding the effects of adiponectin knockout or overexpression in vivo are controversial. While Shinoda et al 48 found no abnormalities regarding bone mass and turnover in Ad -/Ad -mice, Williams et al 49 as well as Oshima et al 50 found an increased bone density. Conversely, adiponectin overexpressing mice had increased bone mass, parameters of bone resorption and bone erosion were not affected. 51 Contrary to what we would have expected based on our results, adenovirus-mediated systemic expression of human adiponectin in collagen-induced arthritis mice reduced clinical disease activity scores of collageninduced arthritis. 52 Most likely, this result refl ects the distinct phenotype of human RASF and the difference between human and murine arthritides.
Several groups also analysed the overexpression or knockdown of adiponectin in mouse models in the metabolic and vascular context. [53] [54] [55] [56] [57] Under special nutritional conditions (high-fat and/or high-glucose diet) or on an obesity background (ob/ob), antidiabetic and anti-atherogenic properties were observed for the overexpression of adiponectin, while adiponectin knockout resulted in insulin resistance and impaired glucose metabolism. Therefore, it is always important to consider the experimental environment when looking at the in-vivo effects of adiponectin.
Also, as yet nothing is known about the role of adiponectin isoforms in mice, their occurrence and distribution. It therefore remains questionable to what extent the existing adiponectin knock-out mouse models are able to provide hints on how adiponectin isoform deprivation would affect human RA.
In conclusion, while adiponectin may present an interesting therapeutic target in RA, more research is required to elucidate whether adiponectin isoforms can be targeted specifi cally and respective inhibitors can be used to provide new therapeutic approaches. Nonetheless, the clearly different potencies of adiponectin isoforms in RA suggest that considering the isoforms may be of value when utilising adiponectin as a marker for risk, activity or progression of RA.
